Summit Therapeutics Inc. Interest Expense On Lease Liabilities
Summit Therapeutics Inc. (SMMT) reported Interest Expense On Lease Liabilities of GBP 30.00 thousand for the 11-month period ending 2019-12-31, per its 20-F filed 2020-04-30.
Discontinued › Expense Statement › Interest Expense
ifrs-full:InterestExpenseOnLeaseLiabilities · last filed 2020-04-30
- Summit Therapeutics Inc. interest expense on lease liabilities for the quarter ending 2019-10-31 was 8.00K GBP, a 20.00% decline year-over-year.
- Summit Therapeutics Inc. interest expense on lease liabilities for the quarter ending 2019-07-31 was 9.00K GBP, a 18.18% decline year-over-year.
- Summit Therapeutics Inc. interest expense on lease liabilities for the quarter ending 2019-04-30 was 9.00K GBP, a 25.00% decline year-over-year.
- Summit Therapeutics Inc. interest expense on lease liabilities for the quarter ending 2019-01-31 was 10.00K GBP.
| Period end | Interest Expense On Lease Liabilities 3 month | Interest Expense On Lease Liabilities 6 month | Interest Expense On Lease Liabilities 9 month | Interest Expense On Lease Liabilities 11 month | Interest Expense On Lease Liabilities 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | 30.00K GBP 20-F · filed 2020-04-30 | ||||
| 2019-10-31 | 8.00K GBP 6-K · filed 2019-12-17 | 17.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | 25.00K GBP 6-K · filed 2019-12-17 | 36.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2019-07-31 | 9.00K GBP 6-K · filed 2019-10-11 | 18.00K GBP 6-K · filed 2019-10-11 | 28.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 38.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2019-04-30 | 9.00K GBP 6-K · filed 2019-06-12 | 19.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 29.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 40.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2019-01-31 | 10.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 20.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 31.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 43.00K GBP 20-F · filed 2020-04-30 | |
| 2018-10-31 | 10.00K GBP 6-K · filed 2019-12-17 | 21.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | 33.00K GBP 6-K · filed 2019-12-17 | ||
| 2018-07-31 | 11.00K GBP 6-K · filed 2019-10-11 | 23.00K GBP 6-K · filed 2019-10-11 | |||
| 2018-04-30 | 12.00K GBP 6-K · filed 2019-06-12 | ||||
| 2018-01-31 | 23.00K GBP 20-F · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |